×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGNX – regenxbio inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/29
07:01 pm
rgnx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
1/29
06:06 pm
rgnx
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
Medium
Report
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
1/29
10:05 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/29
08:03 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Medium
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
1/28
02:16 pm
rgnx
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
Low
Report
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
1/28
11:23 am
rgnx
Regenxbio gene therapy trials suspended by FDA over safety worries [Yahoo! Finance]
Low
Report
Regenxbio gene therapy trials suspended by FDA over safety worries [Yahoo! Finance]
1/28
07:30 am
rgnx
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
High
Report
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
1/27
07:02 pm
rgnx
REGENXBIO (NASDAQ:RGNX) was given a new $37.00 price target on by analysts at Barclays PLC.
High
Report
REGENXBIO (NASDAQ:RGNX) was given a new $37.00 price target on by analysts at Barclays PLC.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/29
04:59 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 27 Filed by: Mills Kenneth T.
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 27 Filed by: Mills Kenneth T.
1/28
08:30 am
rgnx
Form 8-K REGENXBIO Inc. For: Jan 23
High
Report
Form 8-K REGENXBIO Inc. For: Jan 23
1/21
12:27 pm
rgnx
Form SCHEDULE 13G/A REGENXBIO Inc. Filed by: BlackRock Portfolio Management LLC
Low
Report
Form SCHEDULE 13G/A REGENXBIO Inc. Filed by: BlackRock Portfolio Management LLC
1/8
04:45 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: PAKOLA STEVE
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: PAKOLA STEVE
1/8
04:44 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Malzahn Craig
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Malzahn Craig
1/8
04:43 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Simpson Curran
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Simpson Curran
1/8
04:40 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Christmas Patrick J.
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Christmas Patrick J.
1/8
04:33 pm
rgnx
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Chan Mitchell
Medium
Report
Form 4 REGENXBIO Inc. For: Jan 06 Filed by: Chan Mitchell
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
12.1%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
TOP News Decliners
3/11
Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-17.1%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: